Fundraising FoxCOURAGE THERAPEUTICS INC
Newton, US · 2 known investors
Find your way into COURAGE THERAPEUTICS INC
Sign up to see every warm intro you have to COURAGE THERAPEUTICS INC
- Paths you didn't know you had: your email and LinkedIn already hold routes to the COURAGE THERAPEUTICS INC team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Courage Therapeutics is a neuroendocrine biotech developing MC4R agonist drugs for genetic obesity; its lead candidate CTX-B is a weekly injectable targeting melanocortin-4 receptor haploinsufficiency (MC4R HI), a form of early-onset severe obesity with no approved targeted therapy. The company translates research on the melanocortin system into therapeutic candidates for patients with MC4R pathway-driven obesity in the US.
Founders & leadership
Board
Investors · 2
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$4.5M disclosed across 1 round · 2025
▶$4.5MraisedMay 2025 · 14 investors · BiotechnologyRule 506(b)
- Isaac BarchasDirector
- Roger ConeDirector
- Bruce LeutcherDirector
- Daniel HousmanExecutive Officer, Director
- Offering amount
- $10.5M
- Amount sold
- $4.5M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2022 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $250.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $244.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does COURAGE THERAPEUTICS INC do?
- Courage Therapeutics is a neuroendocrine biotech developing MC4R agonist drugs for genetic obesity; its lead candidate CTX-B is a weekly injectable targeting melanocortin-4 receptor haploinsufficiency (MC4R HI), a form of early-onset severe obesity with no approved targeted therapy. The company translates research on the melanocortin system into therapeutic candidates for patients with MC4R pathway-driven obesity in the US.
- Who founded COURAGE THERAPEUTICS INC?
- COURAGE THERAPEUTICS INC was founded by Roger Cone, Dan Housman.
- Who are COURAGE THERAPEUTICS INC's investors?
- COURAGE THERAPEUTICS INC's investors include Arsenal Bridge Venture, Augment Ventures.
- How much funding has COURAGE THERAPEUTICS INC raised?
- COURAGE THERAPEUTICS INC has disclosed $4.5M raised across 1 round.
- Where is COURAGE THERAPEUTICS INC headquartered?
- COURAGE THERAPEUTICS INC is headquartered in Newton, US.